[1]
|
Chirlaque, M., Chen-Liang, T.H., Hurtado, A.M., García Malo, M.D., Ortuño, F.J., Roldán, V., Vicente, V., Jerez, A. and De Arriba, F. (2019) Increasing Therapy-Related Myeloid Neoplasms in Multiple Myeloma. European Journal of Clinical Investigation, 49, Article ID: e13050. https://doi.org/10.1111/eci.13050
|
[2]
|
Mailankody, S., Pfeiffer, R.M., Kristinsson, S.Y., Korde, N., Bjorkholm, M., Goldin, L.R., Turesson, I. and Landgren, O. (2011) Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Multiple Myeloma and Its Precursor Disease (MGUS). Blood, 118, 4086-4092. https://doi.org/10.1182/blood-2011-05-355743
|
[3]
|
Bhatia, S. (2013) Therapy-Related Myelodysplasia and Acute Myeloid Leukemia. Seminars in Oncology, 40, 666-675.
https://doi.org/10.1053/j.seminoncol.2013.09.013
|
[4]
|
Chung, A. and Liedtke, M. (2019) Therapy-Related Myeloid Neoplasms after Treatment for Plasma-Cell Disorders. Best Practice & Research Clinical Haematologyl, 32, 54-64. https://doi.org/10.1016/j.beha.2019.02.003
|
[5]
|
Gupta, S.K., Chandramohan, J. and Kumar, L. (2015) AML Transformation after Autologous Stem Cell Transplant for Multiple Myeloma. BMJ Case Reports, 2015, Article ID: bcr2015210024. https://doi.org/10.1136/bcr-2015-210024
|
[6]
|
Nepstad, I., Hatfield, K.J., Grønningsæter, I.S. and Reikvam, H. (2020) The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cell12s. International Journal of Molecular Sciences, 21, Article No. 2907.
https://doi.org/10.3390/ijms21082907
|
[7]
|
Ramakrishnan, V. and Kumar, S. (2018) PI3K/AKT/mTOR Pathway in Multiple Myeloma: From Basic Biology to Clinical Promise. Leukemia & Lymphoma, 59, 2524-2534. https://doi.org/10.1080/10428194.2017.1421760
|
[8]
|
Harms, M., Gilg, A., Ständker, L., Beer, A.J., Mayer, B., Rasche, V., Gruber, C.W. and Münch, J. (2020) Microtiter Plate-Based Antibody-Competition Assay to determine binding affinities and Plasma/Blood Stability of CXCR4 Ligands. Scientific Reports, 10, Article No. 16036. https://doi.org/10.1038/s41598-020-73012-4
|
[9]
|
Ullah, T.R. (2019) The Role of CXCR4 in Multiple Myeloma: Cells’ Journey from Bone Marrow to Beyond. Journal of Bone Oncology, 17, Article ID: 100253. https://doi.org/10.1016/j.jbo.2019.100253
|
[10]
|
Cory, S., Huang, D.C. and Adams, J.M. (2003) The Bcl-2 Family: Roles in Cell Survival and Oncogenesis. Oncogene, 22, 8590-8607. https://doi.org/10.1038/sj.onc.1207102
|
[11]
|
Linden, M. (2004) Targeted Overexpression of Bcl-XL in B-Lymphoid Cells Results in Lymphoproliferative Disease and Plasma Cell Malignancies. Blood, 103, 2779-2786. https://doi.org/10.1182/blood-2003-10-3399
|
[12]
|
Bolli, N., Biancon, G., Moarii, M., Gimondi, S., Li, Y., de Philippis, C., et al. (2018) Analysis of the Genomic Landscape of Multiple Myeloma Highlights Novel Prognostic Markers and Disease Subgroups. Leukemia, 32, 2604-2616.
https://doi.org/10.1038/s41375-018-0037-9
|
[13]
|
Oka, S., Ono, K. and Nohgawa, M. (2017) Successful Treatment with Azacitidine for the Simultaneous Occurrence of Multiple Myeloma and Acute Myeloid Leukemia with Concomitant del(5q) and the JAK2 V617F Mutation. Annals of Hematology, 96, 1411-1413. https://doi.org/10.1007/s00277-017-3032-8
|
[14]
|
Kumar, R., Srinivasan, V.K., Sharma, P., Aggarwal, R., Prakash, G., Malhotra, P. and Varma, N. (2016) Synchronous Plasma Cell Myeloma and Acute Myeloid Leukemia in a Therapy-Naïve Patient: A Rare Occurrence. Indian Journal of Hematology and Blood Transfusion, 32, 168-172. https://doi.org/10.1007/s12288-015-0628-9
|
[15]
|
Kim, D., Kwok, B. and Steinberg, A. (2010) Simultaneous Acute Myeloid Leukemia and Multiple Myeloma Successfully Treated with Allogeneic Stem Cell Transplantation. Southern Medical Journal, 103, 1246-1249.
https://doi.org/10.1097/smj.0b013e3181fa5eeb
|
[16]
|
Murukutlaa, S., Aroraa, S., Bhatta, V.R., Kediaa, S., Popalzaib, M. and Dhar, M. (2014) Concurrent Acute Monoblastic Leukemia and Multiple Myeloma in a 66-Year-Old Chemotherapy-Naive Woman. World Journal of Oncology, 5, 68-71. https://doi.org/10.14740/wjon722w
|
[17]
|
Wang, L.-Q., Hao, L., Li, X.-X., Li, F.-L., Wang, L.-L., Chen, X.-L. and Hou, M. (2015) A Case of Simultaneous Occurrence of Acute Myeloid Leukemia and Multiple Myeloma. BMC Cancer, 15, Article No. 724.
https://doi.org/10.1186/s12885-015-1743-6
|
[18]
|
Berthon, C., Nudel, M., Boyle, E.M., Goursaud, L., Boyer, T., Marceau, A. and Quesnel, B. (2020) Acute Myeloid Leukemia Synchronous with Multiple Myeloma Successfully Treated by Azacytidine/Lenalidomide and Daratumumab without a Decrease in Myeloid Clone Size. Leukemia Research Reports, 13, Article ID: 100202.
https://doi.org/10.1016/j.lrr.2020.100202
|
[19]
|
El-Shakankiry, N.H., El-Sayed, G.M., El-Maghraby, S. and Moneer, M.M.. (2009) Bcl-2 Protein Expression In Egyptian Acute Myeloid Leukemia. Journal of the Egyptian National Cancer Institute, 21, 71-76.
|
[20]
|
Campos, L., Rouault, J.P., Sabido, O., Oriol, P., Roubi, N., Vasselon, C., et al. (2002) High Expression of Bcl-2 Protein in Acute Myeloid Leukemia Cells Is Associated with Poor Response to Chemotherapy. Blood, 81, 3091-3096.
|
[21]
|
Zhang, H., Wilmot, B., Bottomly, D., Kurtz, S.E., Eide, C.A., Damnernsawad, A., et al. (2018) Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment. Blood, 132, 175.
https://doi.org/10.1182/blood-2018-175
|
[22]
|
Mill, C.P., Cai, T., Fiskus, W., Borthakur, G., Kornblau, S.M., Kadia, T.M., et al. (2018) Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells. Blood, 132, 1351. https://doi.org/10.1182/blood-2018-99-113976
|
[23]
|
Punnoose, E.A., Leverson, J.D., Peale, F., Boghaert, E.R., Belmont, L.D., Tan, N., et al. (2016) Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Molecular Cancer Therapeutics, 15, 1132-1144.
https://doi.org/10.1158/1535-7163.mct-15-0730
|
[24]
|
Touzeau, C., Maciag, P., Amiot, M. and Moreau, P. (2018) Targeting Bcl-2 for the Treatment of Multiple Myeloma. Leukemia, 32, 1899-1907. https://doi.org/10.1038/s41375-018-0223-9
|
[25]
|
Kumar, S.K., Harrison, S.J., Cavo, M. de la Rubia, J., Popat, R., Gasparetto, C, et al. (2020) Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (BELLINI): A Randomised, Double-Blind, Multicentre, Phase 3 Trial. The Lancet Oncology, 21, 1630-1642.
https://doi.org/10.1016/s1470-2045(20)30525-8
|
[26]
|
Guerra, V.A., Di Nardo, C. and Konopleva, M., (2019) Venetoclax-Based Therapies for Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 32, 145-153. https://doi.org/10.1016/j.beha.2019.05.008
|
[27]
|
Tron, A.E., Belmonte, M.A., Adam, A., Aquila, B.M., Boise, L.H., Chiarparin, E., et al. (2018) Discovery of Mcl-1-Specific Inhibitor AZD5991 and Preclinical Activity in Multiple Myeloma and Acute Myeloid Leukemia. Nature Communications, 9, Article No. 5341. https://doi.org/10.1038/s41467-018-07551-w
|